Comparative clinical trial of epsilon amino-caproic acid and tranexamic acid in the prevention of early recurrence of subarachnoid haemorrhage.
A comparative controlled clinical trial of epsilon aminocaproic acid (EACA), 36 g/day and tranexamic acid (TEA), 6 g/day, was undertaken to assess their effectiveness in reducing early recurrence of subarachnoid haemorrhage (SAH). Of 90 patients treated with EACA recurrent haemorrhage was seen in 8% of these patients and 7% of the patients developed delayed ischaemic deficit. The total pre-operative mortality in EACA-group was 11%. Of 61 patients treated with TEA, 10% had recurrent haemorrhage and delayed ischaemic deficit occurred in 5% of the patients. The total pre-operative mortality in TEA-group was 11%. No difference was found between the effectiveness and side-effects of these drugs.
D000293:Adolescent; D000328:Adult; D000614:Aminocaproates / Q000627:therapeutic use*; D015119:Aminocaproic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D012008:Recurrence; D013345:Subarachnoid Hemorrhage / Q000401:mortality / Q000517:prevention & control*; D014148:Tranexamic Acid / Q000009:adverse effects / Q000627:therapeutic use*
D000614:Aminocaproates; D003509:Cyclohexanecarboxylic Acids; D014148:Tranexamic Acid; D015119:Aminocaproic Acid